Elsevier

Joint Bone Spine

Volume 74, Issue 1, January 2007, Pages 52-55
Joint Bone Spine

Original article
Plasma levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever

https://doi.org/10.1016/j.jbspin.2006.02.003Get rights and content

Abstract

Aims

To assess the levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in patients with familial Mediterranean fever (FMF).

Methods

Plasma levels of sVEGFR-1 were investigated in 33 FMF patients in an attack-free period (mean age 30.8 years; males/females 10/23), in 15 patients with acute FMF attack (mean age 32.7 years; males/females 7/8), and 19 healthy controls (mean age 32 years; males/females 11/8). Levels of sVEGFR-1 were also compared among patients who were receiving colchicine and those who were not.

Results

Plasma sVEGFR-1 levels were 3.49 ± 1.10, 3.53 ± 1.02, and 0.37 ± 0.28 ng/ml for FMF patients in the attack-free period, FMF patients with acute attack, and healthy controls, respectively. Plasma sVEGFR-1 levels were significantly higher in FMF patients with and without acute attack compared to the control group (p < 0.05). sVEGFR-1 levels were not statistically significant between patients with acute attack and attack-free FMF patients (p > 0.05). The plasma levels of sVEGFR-1 were also comparable in colchicine treated and untreated patients.

Conclusion

Our data suggest that sVEGFR-1 may have a role in the ongoing inflammatory cascade in FMF.

Introduction

Familial Mediterranean fever (FMF) is an autosomal recessive disease, which affects primarily Turks, Armenians, Arabs and Jews [1]. FMF is characterized by self-limiting acute febrile attacks and inflammatory reactions of serosal membranes. Several non-specific immunological abnormalities and elevations in acute-phase reactant levels were observed during FMF attacks [2]. Moreover, we—along with others—have previously demonstrated evidence for ongoing subclinical inflammation, even during attack-free periods in FMF patients [3], [4], [5].

Vascular endothelial growth factor (VEGF), a member of the platelet-derived growth factor family, is a potent and specific mitogen for endothelial cells [6], [7]. VEGF was originally thought to be an endothelial cell-derived, angiogenic, autocrine factor. However, recent reports have shown that various other cell types including macrophages [8], [9] and neutrophils [10], [11] also express significant amounts of VEGF. VEGF receptors 1 and 2 (VEGFR-1 and VEGFR-2) are the two high-affinity tyrosine kinase receptors for VEGF. VEGFR-1 gene encodes two polypeptides, a soluble VEGF-binding protein (sVEGFR-1) and a full-length membrane protein (receptor form of VEGFR-1) [12]. sVEGFR-1 is a naturally occurring VEGF antagonist, and is proved to inhibit the VEGF induced proliferation and migration of endothelial cells in vitro [13], [14], [15]. sVEGFR-1 has a physiological function in pregnancy by regulating the VEGF in a negative manner by down-regulating its activity [16]. sVEGFR-1 was detected in serum and plasma samples of normal healthy donors but the biological and physiological significance of it in vivo is not yet clear [13].

Increased VEGF levels in the circulation have been reported in a number of vascular and inflammatory diseases, including systemic vasculitis and inflammatory arthritis [17], [18], [19], [20], [21], [22]. Therefore, VEGF seems to be a non-specific marker of diseases in which endothelial cell injury and/or repair occurs. On the other hand, circulating levels of sVEGFR-1 were also increased in inflammatory arthritis [21]. In this study, we assessed sVEGFR-1 levels in patients with FMF.

Section snippets

Methods

The study groups comprised 33 FMF patients in an attack-free period (mean age 30.8 years (range 16–47); males/females 10/23), and 15 patients with acute FMF attack (mean age 32.7 years (range 19–50); males/females 7/8). All of the patients had had acute febrile peritonitis attacks. Sixteen patients had experienced arthritis (33.3%), 8 patients had had pleuritis (16.7%), and one patient had had pericarditis (2.1%) before the diagnosis of FMF. One patient was complicated with amyloidosis. The

Results

Age and sex distributions in different groups were similar. The disease durations were also comparable in patients in attack-free periods and patients with acute FMF attacks (Table 2). The levels of plasma sVEGFR-1 were expressed as mean and standard deviation (SD). Plasma sVEGFR-1 levels were 3.49 ± 1.10, 3.53 ± 1.02, and 0.37 ± 0.28 ng/ml for FMF patients in an attack-free period, FMF patients with acute attack, and healthy controls, respectively (Table 2). Plasma sVEGFR-1 levels were significantly

Discussion

In this study, we demonstrated that plasma sVEGFR-1 levels increased in patients with FMF with and without acute attacks. Plasma levels of sVEGFR-1 were comparable in patients with acute FMF attack and in attack-free periods. sVEGFR-1 values were independent of colchicine use.

Recurrent and self-limiting febrile attacks of polyserositis are characteristic features of FMF. Serum concentrations of acute phase proteins and proinflammatory cytokines are elevated in FMF patients during acute attacks.

References (29)

  • M. Ancelin et al.

    Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism

    Lab Invest

    (2004)
  • P.A. Anton et al.

    Enhanced neutrophil chemiluminescence in familial Mediterranean fever

    J Clin Immunol

    (1988)
  • M. Bar-Eli et al.

    A neutrophil lysozyme leak in patients with familial Mediterranean fever

    Am J Hematol

    (1981)
  • S. Kiraz et al.

    Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever

    Clin Exp Rheumatol

    (1998)
  • Cited by (8)

    • Circulating adrenomedullin levels in ankylosing spondylitis and Familial Mediterranean Fever

      2008, Joint Bone Spine
      Citation Excerpt :

      Moreover, there is evidence demonstrating the presence of sustained subclinical inflammation in the attack-free periods of FMF as evidenced by elevated levels of certain proinflammatory cytokines [16]. There are some data that endothelial injury and/or activation may occur during the clinical course of FMF [17,18]. In this study, we investigated plasma AM levels in patients with AS and in FMF patients with acute attacks.

    • Assessment of aortic wall stiffness in patients with Familial Mediterranean Fever

      2008, Joint Bone Spine
      Citation Excerpt :

      Briefly, induction of atherosclerotic process may cause the increased aortic stiffness. In addition to this, we have recently demonstrated that various markers of endothelial activation and/or injury including soluble vascular endothelial growth factor receptor-1 and thrombomodulin were increased in patients with FMF, suggesting that endothelial cells may contribute to the inflammatory cascade of FMF [23,24]. The other possible pathophysiological link is elevated levels of cytokines such as; tumor necrosis factor alpha (TNF-α), soluble interleukin-2 receptor, interleukin-1b, interleukin-6, and interleukin-8, IL-12, and TNF-α, may encourage the degradation of collagen and elastin content of the aortic intima and may, thus, contribute to impaired function and dilation of the aorta [25–30].

    View all citing articles on Scopus
    View full text